Zenas Biopharma (NASDAQ:ZBIO) Earns Outperform Rating from Analysts at Wedbush

Equities research analysts at Wedbush initiated coverage on shares of Zenas Biopharma (NASDAQ:ZBIO) in a research note issued on Thursday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $35.00 price target on the stock. Wedbush’s target price would suggest a potential upside of 320.17% from the company’s previous close.

Separately, Guggenheim reiterated a “buy” rating and set a $45.00 price target on shares of Zenas Biopharma in a report on Wednesday, March 12th.

Zenas Biopharma Trading Down 2.2 %

Shares of ZBIO stock opened at $8.33 on Thursday. Zenas Biopharma has a fifty-two week low of $5.83 and a fifty-two week high of $26.25. The stock has a market capitalization of $348.19 million and a price-to-earnings ratio of -2.35.

About Zenas Biopharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.